PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-50.43%
Both yoy net incomes decline, with GNPX at -546.03%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
7.46%
D&A growth of 7.46% while GNPX is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
46.91%
Deferred tax of 46.91% while GNPX is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
9.40%
Less SBC growth vs. GNPX's 1133.46%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
-262.74%
Negative yoy working capital usage while GNPX is 831.43%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-225.01%
Negative yoy AP while GNPX is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
155.76%
Growth well above GNPX's 28.43%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
9.40%
Lower 'other non-cash' growth vs. GNPX's 3260.97%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
-30.81%
Negative yoy CFO while GNPX is 43.40%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
49.68%
Some CapEx rise while GNPX is negative at -407.34%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Purchases growth of 100.00% while GNPX is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We have some outflow growth while GNPX is negative at -407.34%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
82.07%
We have mild expansions while GNPX is negative at -407.34%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
-1.11%
We cut debt repayment yoy while GNPX is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
207.88%
Issuance growth of 207.88% while GNPX is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.